Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.14 +0.9%	$1.89	$0.77 ▼ $4.08	$295.93M	1.4	926,063 shs	411,152 shs
HUMA Humacyte	$2.68 -3.2%	$1.71	$1.15 ▼ $9.97	$415.72M	1.64	3.80 million shs	5.79 million shs
IMMP Immutep	$1.91 -3.0%	$1.75	$1.32 ▼ $3.05	$278.93M	1.8	218,080 shs	106,718 shs
JUSHF Jushi	$0.29 -1.3%	$0.32	$0.22 ▼ $0.69	$57.50M	-0.86	206,752 shs	49,910 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	+0.94%	+2.39%	+15.05%	-26.21%	+45.58%
HUMA Humacyte	-3.25%	+5.93%	+84.83%	-21.18%	-65.24%
IMMP Immutep	-3.05%	-1.55%	+11.70%	-1.04%	-31.79%
JUSHF Jushi	-1.32%	-5.68%	-29.54%	-6.28%	-51.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	4.0402 of 5 stars	4.6	3.0	3.4	5.0	0.0
HUMA Humacyte	2.4779 of 5 stars	3.5	1.0	3.3	2.5	0.6
IMMP Immutep	1.2596 of 5 stars	3.5	1.0	2.4	0.0	0.0
JUSHF Jushi	1.4073 of 5 stars	0.0	5.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.11	Buy	$13.13	513.32% Upside
HUMA Humacyte	3.00	Buy	$11.71	337.10% Upside
IMMP Immutep	3.00	Buy	$7.00	266.49% Upside
JUSHF Jushi	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest JUSHF, CMPX, IMMP, and HUMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/14/2025	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $14.00
5/13/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/4/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $24.00
4/2/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/2/2025	CMPX Compass Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $6.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	348.15	N/A	N/A	$1.17 per share	1.83
HUMA Humacyte	$517K	804.10	N/A	N/A	$0.13 per share	20.62
IMMP Immutep	$5.14M	54.27	N/A	N/A	$1.05 per share	1.82
JUSHF Jushi	$269.45M	0.21	N/A	N/A	($0.04) per share	-7.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	8/11/2025 (Estimated)
HUMA Humacyte	-$110.78M	-$0.69	N/A	N/A	N/A	N/A	-942.81%	-93.82%	8/12/2025 (Estimated)
IMMP Immutep	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
JUSHF Jushi	-$65.10M	-$0.24	N/A	N/A	N/A	-20.93%	N/A	-10.45%	8/6/2025 (Estimated)

Latest JUSHF, CMPX, IMMP, and HUMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q1 2025	JUSHF Jushi	-$0.06	-$0.09	-$0.03	-$0.09	$66.23 million	$63.85 million
3/28/2025	Q4 2024	HUMA Humacyte	-$0.23	-$0.16	+$0.07	-$0.16	$0.64 million	$7.23 million
3/12/2025	Q4 2024	JUSHF Jushi	-$0.04	-$0.06	-$0.02	-$0.06	$64.03 million	$65.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
IMMP Immutep	N/A	N/A	N/A	N/A	N/A
JUSHF Jushi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	31.84	31.84
HUMA Humacyte	N/A	1.10	1.10
IMMP Immutep	0.01	18.25	18.25
JUSHF Jushi	N/A	1.17	0.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
HUMA Humacyte	44.71%
IMMP Immutep	2.32%
JUSHF Jushi	21.68%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
HUMA Humacyte	5.10%
IMMP Immutep	3.07%
JUSHF Jushi	22.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
HUMA Humacyte	150	155.12 million	111.76 million	Optionable
IMMP Immutep	2,021	146.04 million	141.09 million	Optionable
JUSHF Jushi	1,188	196.63 million	154.04 million	Not Optionable

JUSHF, CMPX, IMMP, and HUMA Headlines

Recent News About These Companies

Q2 Earnings Estimate for Jushi Issued By Atb Cap Markets

May 16, 2025 | marketbeat.com

Jushi (OTCMKTS:JUSHF) Releases Earnings Results

May 12, 2025 | marketbeat.com

Jushi Holdings Inc. Earnings Call: Mixed Sentiments and Strategic Expansion

May 9, 2025 | tipranks.com

Jushi Holdings Inc. (JUSHF) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Jushi Holdings Inc. (JUSHF) Reports Q1 Loss, Lags Revenue Estimates

May 8, 2025 | zacks.com

Jushi Holdings Reports Q1 2025 Financial Results and Expansion Plans

May 8, 2025 | tipranks.com

Jushi Holdings Inc. Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Jushi (JUSHF) Projected to Post Earnings on Thursday

May 3, 2025 | marketbeat.com

Jushi Holdings Inc. Updates Call Time to 4:00 p.m. Eastern Time to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | financialpost.com

Jushi Holdings Inc. Updates Call Time to 4:00 p.m. Eastern Time to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | globenewswire.com

Jushi Holdings Inc. (OTCMKTS:JUSHF) Short Interest Update

May 1, 2025 | marketbeat.com

Economic impact of U.S. cannabis industry set to double over next six years

April 25, 2025 | msn.com

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025 | JUSHF Stock News

April 23, 2025 | gurufocus.com

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025 | JUSHF Stock News

April 23, 2025 | gurufocus.com

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025

April 23, 2025 | globenewswire.com

Jushi Holdings Expands Ohio Presence with New Mansfield Dispensary

April 18, 2025 | tipranks.com

Jushi Holdings Inc. Announces Grand Opening of Beyond Hello™ Mansfield in Ohio, Expanding Its Statewide Retail Footprint

April 18, 2025 | globenewswire.com

Former COO alleges Jushi fired him for trying to maintain safety measures

April 5, 2025 | greenmarketreport.com

Jushi Holdings announces Ohio retail updates, opening of Beyond Hellow Warren

March 19, 2025 | msn.com

Jushi Holdings Expands Ohio Presence with New Dispensary Opening

March 19, 2025 | tipranks.com

Jushi Holdings Inc. Announces Ohio Retail Updates Including the Opening of Beyond Hello™ Warren, Expanding Its Presence in Ohio’s Emerging Adult-Use Market

March 19, 2025 | financialpost.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUSHF, CMPX, IMMP, and HUMA Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.14 +0.02 (+0.94%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.12 -0.02 (-0.93%)

As of 05/30/2025 07:28 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Humacyte NASDAQ:HUMA

$2.68 -0.09 (-3.25%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.68 +0.00 (+0.19%)

As of 05/30/2025 07:58 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Immutep NASDAQ:IMMP

$1.91 -0.06 (-3.05%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.92 +0.01 (+0.52%)

As of 05/30/2025 05:27 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Jushi OTCMKTS:JUSHF

$0.29 0.00 (-1.32%)

As of 05/30/2025 03:36 PM Eastern

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time